Pharmaceutical

Noticing biosimilar competition on the horizon, Roche Holding (OTCMKTS:RHHBY)(VTX:ROG) is aggressively pushing ahead with its late-stage pipeline drugs. In particular, Roche is placing its best on a PD-L1 cancer drug atezolizumab.

Noticing biosimilar competition on the horizon, Roche Holding (OTCMKTS:RHHBY)(VTX:ROG) is aggressively pushing ahead with its late-stage pipeline drugs. In particular, Roche is placing its best on a PD-L1 cancer drug atezolizumab.
According to the article on Fierce Biotech:

Roche is late to the immuno-oncology market. An aggressive Merck (NYSE:MRK) has been jockeying with market leader Bristol-Myers Squibb (NYSE:BMY) in the drive on landmark approvals, riding their drug Keytruda as Bristol-Myers pushes Opdivo toward more regulatory successes. Those are PD-1 drugs, though, giving Roche a shot at first-mover status on the PD-L1 side of IO, which is dismantling cancer cells’ cloak of invisibility and unleashing an immune system assault.

 
Click here to read the full article on Fierce Biotech.

MARKETS

Markets
TSX19062.91+345.79
TSXV647.33+15.54
DOW31500.68+823.32
S&P 5003911.74+116.01
NASD11607.62+375.43
ASX6528.40+19.90

COMMODITIES

Commodities
Gold1827.54+0.47
Silver21.15+0.03
Copper3.740.00
Palladium1879.51+6.50
Platinum911.26+4.32
Oil107.06+2.79
Heating Oil4.24+0.02
Natural Gas6.17-0.07

DOWNLOAD FREE REPORTS

×